---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-013742"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:19:28.904349+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CorMedix appoints Joseph Todisco as CEO effective by May 16, 2022

## Summary
- Joseph Todisco appointed CEO; expected start on or before May 16, 2022; will also join Board.
- Todisco previously EVP, Chief Commercial Officer at Amneal; 20+ years pharma experience.
- Employment agreement: $600k base salary, 65% target bonus, 500k stock options, 207k RSUs.
- Dr. Matt David to continue as Interim CEO/CFO until Todisco starts, then remain CFO.
- Company reaffirms focus on DefenCath NDA resubmission and commercial launch preparation.

## SEC filing metadata
- accession: 0001213900-22-013742
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/0001213900-22-013742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/ea157150-8k_cormedixinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-013742
- JSON: https://secwatch.observer/filing/0001213900-22-013742.json
- Plain text: https://secwatch.observer/filing/0001213900-22-013742.txt

## Key facts
- Executive change
  Joseph Todisco was appointed as Chief Executive Officer at CorMedix Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Joseph Todisco as the Chief Executive Officer, commencing on such date as mutually agreed by Mr. Todisco and the Board, but in no event later than May 16, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/0001213900-22-013742-index.htm
- Executive change
  Joseph Todisco was appointed as Director at CorMedix Inc..
  - Action: appointed
  - Role: Director
  source text: Mr. Todisco was appointed to serve as a member of the Board on March 18, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/0001213900-22-013742-index.htm
- Executive change
  Matthew T. David changed role as Chief Financial Officer at CorMedix Inc..
  - Role: Chief Financial Officer
  source text: Dr. Matthew T. David will continue to serve as Interim Chief Executive Officer and Chief Financial Officer until Mr. Todisco commences employment, after which Dr. David will continue to serve as our Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390022013742/0001213900-22-013742-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.